LeMaitre Vascular(US:LMAT)2026-02-25 23:02Financial Data and Key Metrics Changes - Q4 2025 featured 16% sales growth, with a gross margin of 71.7% and operating income growth of 47% [4] - Q4 fully diluted earnings per share (EPS) were $0.68, a 39% increase year-over-year [8] - For the full year 2025, organic revenue growth was 14%, with adjusted EPS growth of 23% [9] Business Line Data and Key Metrics Changes - Sales growth in Q4 was led by grafts (up 27%), valvulotomes (up 20%), and shunts (up 18%) [4] - RFA Vascular grew 19% and RFA Cardiac grew 90% in Q4 [4] - Artegraft grew 29% worldwide in Q4, with international sales reaching $1.9 million in Q4 and $4 million for the full year 2025 [4] Market Data and Key Metrics Changes - EMEA region grew 29%, APAC grew 20%, and the Americas grew 10% in Q4 [4] - International sales are expected to reach approximately $10 million in 2026, contributing $6 million of sales growth for the year [4] Company Strategy and Development Direction - The company aims to produce quality devices, build its vascular sales force, go direct in new countries, acquire niche products, and focus on profitability, cash flow, and dividends [7] - The 2026 U.S. price list reflects a blended 8% increase across the portfolio, with early results indicating hospital acceptance [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating 12% sales growth and 21% adjusted operating income growth [9] - The company is focused on niche markets and believes it is well-positioned for another successful year in 2026 [12] Other Important Information - The company ended 2025 with $359 million in cash and securities, and free cash flow for the year was $74.5 million [9] - A cyber incident in January 2026 had minimal impact on sales and operations, with adequate insurance coverage [10] Q&A Session Summary Question: Factors for achieving operating growth in 2026 - Management highlighted stable headcount, sales pricing growth, and improved manufacturing efficiency as key factors for operating leverage [16] Question: Outlook for future price increases - Management noted that the smoother transition for price increases this year was due to earlier communication and preparation [17][19] Question: M&A strategy and targets - The company is actively pursuing M&A opportunities in open vascular and cardiac surgery, with a focus on revenues between $15 million and $150 million [30][31] Question: Performance of Artegraft and market potential - Management revised the total addressable market (TAM) for Artegraft in Europe to $30 million, indicating stronger than expected performance [33] Question: Updates on the European market and MDR approvals - The company has been aggressive with MDR approvals, gaining market share as competitors faced challenges [44][46] Question: Performance in China - Revenue in China grew 24% in Q4, with the company now profitable in that market for the first time [47][48] Question: Valvulotome sales growth - Management attributed the 20% growth in valvulotomes to a well-established sales channel and effective marketing [50][56] Question: Guidance for 2026 tax rate and share count - The tax rate for 2026 is expected to be around 23.2%, with share count remaining stable [100] Question: Approval status for RestoreFlow in Ireland - Approval for RestoreFlow in Ireland is now expected in Q3 2026, delayed from previous expectations [103]